focus -WSS

focus

author：Wikipedia 2025-08-31 02:00:06 - browse：9831

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： The FDA weighs the risks of candy

hotspot

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

Maker of FluMist seeks to allow at

WHO may add ‘noma' to its list of neglected tropical diseases

Readout Newsletter: What happened with Sarepta's Duchenne data

Meta's Zuckerberg and Chan on track to put $50 billion into science

RaDonda Vaught case: a double standard for nurses, physicians

knowledge

focus

explore

Medical records are filled with copy

Telehealth options flood the market as retailers push virtual care

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why Sanofi got shellacked over its spinoff

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

4th of July breaks record for highest global temperature ever measured

The high cost of giving birth even with insurance

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Guidelines to prevent youth baseball injuries need more muscle

Emergency medicine has repudiated 'excited delirium.' Now what?

hotspot

Readout Newsletter: New research from Sanofi, Regeneron, etc.

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Emergency medicine has repudiated 'excited delirium.' Now what?

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

RaDonda Vaught case: a double standard for nurses, physicians

7 people shot in DC, police say

entertainment

hotspot

focus

hotspot